Prime Therapeutics LLC recently released the results of two studies focused on two classes of high-cost biologics, asthma and hereditary angioedema (HAE). Both conditions have seen new therapies recently and may be candidates for value-based contracts.
While more than 25 million people in the United States suffer from asthma, about 5% to 10% of those suffer from severe allergic or eosinophilic asthma. While asthma overall has a societal cost of around $56 billion, those patients account for almost 50% of that cost. Global Initiative for Asthma 2019 guidelines recommend an asthma biologic for this subset of patients, and the first Prime study examined the use of five biologics: Cinqair (reslizumab), Dupixent (dupilumab), Fasenra (benralizumab), Nucala (mepolizumab) and Xolair (omalizumab).